Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 8 (2)

Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application

Affiliations
Review

Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application

Christopher A Kerantzas et al. mBio.

Abstract

Tuberculosis is a global health problem that causes the death of approximately 1.5 million people worldwide each year (WHO, p. 1-126, Global Tuberculosis Report, 2015). Treatment of drug-susceptible tuberculosis requires combination antimicrobial therapy with a minimum of four antimicrobial agents applied over the course of 6 months. The first instance of combination antimicrobial therapy applied to tuberculosis was the joint use of streptomycin and para-aminosalicylic acid as documented by the Medical Research Council of the United Kingdom in 1950. These antimicrobial drugs were the product of many decades of investigation into both organism-derived antibiotics and synthetic chemotherapy and were the first agents in those respective categories to show substantial clinical efficacy and widespread use for tuberculosis. The events leading to the discovery and application of these two agents demonstrate that investments in all aspects of research, from basic science to clinical application, are necessary for the continued success of science in finding treatments for human disease. This observation is especially worth considering given the expanded role that combination therapy may play in combating the current rise in resistance to antimicrobial drugs.

Similar articles

See all similar articles

Cited by 14 PubMed Central articles

See all "Cited by" articles

References

    1. WHO 2015. Global tuberculosis report 2015, p 1–126. World Health Organization, Geneva, Switzerland.
    1. WHO 1994. TB: A global emergency. World Health Organization, Geneva, Switzerland.
    1. WHO 2011. Tuberculosis control in the western Pacific region −2010 report. WPRO, Manila, Philippines.
    1. Pyle MM. 1947. Relative numbers of resistant tubercle bacilli in sputa of patients before and during treatment with streptomycin. Proc Staff Meet Mayo Clin 22:465–473. - PubMed
    1. Eldholm V, Balloux F. 2016. Antimicrobial resistance in Mycobacterium tuberculosis: the odd one out. Trends Microbiol 24:637–648. doi:10.1016/j.tim.2016.03.007. - DOI - PubMed

MeSH terms

Feedback